https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1046431/Vaccine-surveillance-report-week-2-2022.pdf#page=6&zoom=100,53,94 Vaccine effectiveness against the Omicron variant Method： A test negative case control design was used to estimate vaccine effectiveness (VE) against symptomatic COVID-19 with the Omicron variant compared to the Delta variant. Here vaccination rates in PCR positive cases are compared to vaccination rates in those who test negative. Individuals who reported symptoms and tested in pillar 2 (community testing) between November 27 and January 6 2022 were included in the analysis. Results： The symptomatic disease test negative case control analysis included 236,023 Delta cases and 760,647 Omicron cases. In all periods, effectiveness (against symptomatic disease) was lower for Omicron compared to Delta. Among those who had received 2 doses of AstraZeneca, effectiveness dropped from 45 to 50% to almost no effect against Omicron from 20 weeks after the second dose. Among those who had received 2 doses of Pfizer or Moderna effectiveness dropped from around 65 to 70% down to around 10% by 20 weeks after the 2nd dose. 2 to 4 weeks after a booster dose vaccine effectiveness ranged from around 65 to 75%, dropping to 55 to 65% at 5 to 9 weeks and 45 to 50% from 10+ weeks after the booster. Vaccine Effectiveness against symptomatic disease
整体感觉booster对于防止omicron有症状感染是有明显的作用。但是drop的也比较快。 （最下面图表很直观） 欢迎讨论和分享，尤其是有数据支持的。不支持疫苗的请勿在此无谓争吵。 谢谢大家！
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1046431/Vaccine-surveillance-report-week-2-2022.pdf#page=6&zoom=100,53,94
Vaccine effectiveness against the Omicron variant
Method： A test negative case control design was used to estimate vaccine effectiveness (VE) against symptomatic COVID-19 with the Omicron variant compared to the Delta variant. Here vaccination rates in PCR positive cases are compared to vaccination rates in those who test negative. Individuals who reported symptoms and tested in pillar 2 (community testing) between November 27 and January 6 2022 were included in the analysis.
Results： The symptomatic disease test negative case control analysis included 236,023 Delta cases and 760,647 Omicron cases. In all periods, effectiveness (against symptomatic disease) was lower for Omicron compared to Delta. Among those who had received 2 doses of AstraZeneca, effectiveness dropped from 45 to 50% to almost no effect against Omicron from 20 weeks after the second dose. Among those who had received 2 doses of Pfizer or Moderna effectiveness dropped from around 65 to 70% down to around 10% by 20 weeks after the 2nd dose. 2 to 4 weeks after a booster dose vaccine effectiveness ranged from around 65 to 75%, dropping to 55 to 65% at 5 to 9 weeks and 45 to 50% from 10+ weeks after the booster.
Vaccine Effectiveness against symptomatic disease
这个数据是英国高峰时期统计的啊，而且美国目前还在峰顶...
美国顶峰一月六号就过了，估计当天实际感染六百万人，现在看到的数字只不过是测试延迟罢了。本来模型预测一月九号的，但是美国人民节日太欢乐了。